Results 11 to 20 of about 769 (122)

A Mini-Review of In Vitro Data for Candida Species, Including C. auris, Isolated during Clinical Trials of Three New Antifungals: Fosmanogepix, Ibrexafungerp, and Rezafungin [PDF]

Journal of Fungi
This mini-review summarizes the clinical outcomes and antifungal susceptibility results, where available, for three new antifungals, including fosmanogepix, ibrexafungerp, and rezafungin, against Candida isolates cultured from patients in clinical trials.
Ana Espinel-Ingroff, Nathan P. Wiederhold   +1 more
doaj   +7 more sources

Fosmanogepix: A Review of the First-in-Class Broad Spectrum Agent for the Treatment of Invasive Fungal Infections [PDF]

Journal of Fungi, 2020
Fosmanogepix is a first-in-class antifungal currently in Phase 2 clinical trials for the treatment of invasive fungal infections caused by Candida, Aspergillus and rare molds. Fosmanogepix is the N-phosphonooxymethylene prodrug of manogepix, an inhibitor
Karen Joy Shaw, Ashraf S. Ibrahim
doaj   +8 more sources

Fosmanogepix for the Treatment of Invasive Mold Diseases Caused by Aspergillus Species and Rare Molds: A Phase 2, Open-Label Study (AEGIS). [PDF]

Clin Infect Dis
Background Fosmanogepix (FMGX) inhibits glycosylphosphatidylinositol anchored cell wall transfer protein 1, essential for anchoring mannoproteins to fungal cell wall, critical for host invasion.
Hodges MR, Tawadrous M, Cornely OA, Thompson GR, Slavin MA, Maertens JA, Dadwal SS, Rahav G, Hazel S, Almas M, Jakate A, Pypstra R.   +11 more
europepmc   +6 more sources

840 Limb Salvage After Lomentospora Osteomyelitis in a Burn-Injured Patient Treated with Fosmanogepix [PDF]

J Burn Care Res
Introduction Burn patients are highly susceptible to infections due to factors like loss of the protective skin barrier, immunosuppression, prolonged open wounds, mechanical ventilation and invasive lines.
G Sani, Ian A. Powelson, Derek J. Bays, Sierra Young, Erin Louie, Jason Heard   +5 more
europepmc   +4 more sources

Phase 1b safety and pharmacokinetics of intravenous and oral fosmanogepix in patients with acute myeloid leukaemia and neutropenia. [PDF]

J Antimicrob Chemother, 2023
Objectives Fosmanogepix (APX001), a first-in-class, intravenous (IV) and oral (PO) antifungal prodrug, is being developed to treat invasive fungal diseases (IFDs).
Cornely OA, Ostermann H, Koehler P, Teschner D, Limburg E, Kramer WG, Barbat SH, Tawadrous M, Hodges MR.   +8 more
europepmc   +6 more sources

Fosmanogepix: The Novel Anti-Fungal Agent's Comprehensive Review of in Vitro, in Vivo, and Current Insights From Advancing Clinical Trials. [PDF]

Cureus
Fosmanogepix, a prodrug of Manogepix (MGX), is a groundbreaking antifungal agent with broad-spectrum activity against yeasts, including Cryptococcus and Candida, as well as molds.
Almajid A, Bazroon A, Al-Awami HM, Albarbari H, Alqahtani I, Almutairi R, Alsuwayj A, Alahmadi F, Aljawad J, Alnimer R, Asiri N, Alajlani S, Alshelali R, Aljishi Y.   +13 more
europepmc   +6 more sources

Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial. [PDF]

J Antimicrob Chemother, 2023
Background Fosmanogepix is a first-in-class antifungal targeting the fungal enzyme Gwt1, with broad-spectrum activity against yeasts and moulds, including multidrug-resistant fungi, formulated for intravenous (IV) and oral administration.
Pappas PG, Vazquez JA, Oren I, Rahav G, Aoun M, Bulpa P, Ben-Ami R, Ferrer R, Mccarty T, Thompson GR, Schlamm H, Bien PA, Barbat SH, Wedel P, Oborska I, Tawadrous M, Hodges MR.   +16 more
europepmc   +10 more sources

Phase 1 drug-drug interaction study to assess the effect of CYP3A4 inhibition and pan-CYP induction on the pharmacokinetics and safety of fosmanogepix in healthy participants. [PDF]

Antimicrob Agents Chemother
Immunocompromised patients are susceptible to fungal infections, and drug-drug interactions with antifungals may occur due to concomitant medications.
Hodges MR, van Marle S, Kramer WG, Ople E, Tawadrous M, Jakate A.   +5 more
europepmc   +5 more sources

P-1192. Fosmanogepix Expanded Access Experience in Patients With Invasive Aspergillosis [PDF]

Open Forum Infect Dis
Background Fosmanogepix (FMGX; prodrug, active moiety manogepix) is the first member of the “gepix” antifungal class. FMGX inhibits Gwt1, depleting GPI-anchor proteins important for fungal cell wall integrity.
Jana Dickter, Alfredo Puing, Esther Fiz Benito, Jannik Stemler, Apurva Amit Akkad, Juergen Prattes, Ana Belkin, Julie M. Steinbrink, Omer E. Beaird, Haran T. Schlamm, Sanjeet Dadwal, Luis Ostrosky-Zeichner   +11 more
europepmc   +4 more sources

Fosmanogepix (APX001) Is Effective in the Treatment of Pulmonary Murine Mucormycosis Due to Rhizopus arrhizus [PDF]

Antimicrobial Agents and Chemotherapy, 2020
Mucormycosis is a life-threatening infection with high mortality that occurs predominantly in immunocompromised patients. Manogepix (MGX) is a novel antifungal that targets Gwt1, a protein involved in an early step in the conserved glycosylphosphotidyl ...
Teclegiorgis Gebremariam, Sondus Alkhazraji, Abdullah Alqarihi, Nathan P. Wiederhold, Karen Joy Shaw, Thomas F. Patterson, Scott G. Filler, Ashraf S. Ibrahim   +7 more
semanticscholar   +5 more sources